Suppr超能文献

伴有门静脉血栓形成的肝细胞癌中代谢蛋白的下调

Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis.

作者信息

Lee Wei-Chen, Chou Hong-Shiue, Wu Ting-Jung, Lee Chen-Fang, Hsu Pao-Yueh, Hsu Hsiu-Ying, Wu Tsung-Han, Chan Kun-Ming

机构信息

Division of Liver and Transplantation Surgery, Department of General Surgery, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, 5, Fu-Hsing Street, Kwei-Shan Township, Taoyuan, Taiwan.

出版信息

Clin Proteomics. 2017 Aug 2;14:29. doi: 10.1186/s12014-017-9164-y. eCollection 2017.

Abstract

BACKGROUND

Hepatocellular carcinoma is an aggressive malignancy with poor prognosis and easy to recur even the tumor is totally removed by surgery. Portal vascular invasion is one of the major factors contributing to tumor recurrence and poor prognosis. However, why hepatocellular carcinoma is easy to grow into vessels is unclear.

METHODS

Surgical specimens from seven hepatocellular carcinoma patients with portal vein thrombosis and seven patients without vascular invasion were utilized to analyze protein expression by proteomic technique. The proteins in the tumors were separated by 2-dimensional electrophoresis. Protein patterns in the gels were recorded as digitalized images. The differences of expression in hepatocellular carcinoma with or without portal vein thrombosis were identified by mass spectrometry.

RESULTS

Clinically, the tumors with portal vein thrombosis were larger than those without portal vein thrombosis. The median survival time for the patients with portal vein thrombosis was much shorter [4 (ranged 2.5-47) vs. 53 (ranged 33-85) months,  = 0.002]. By analyzing the protein expression in cancer tissues with or without portal vein thrombosis, the differences of protein expression were mainly metabolic enzymes. Carbonic anhydrase I, betaine-homocysteine -methyltransferase 1, fumarate hydratase, isovaleryl-CoA dehydrogenase, short-chain specific acyl-CoA dehydrogenase and arginase-1 were all down-regulated in the tumors with portal vein thrombosis.

CONCLUSION

Metabolic enzymes and cytosol carbonic anhydrases were downregulated in hepatocellular carcinoma with portal vein thrombus. The deficiency of metabolic enzymes and cytosol carbonic anhydrases may alter cellular metabolisms and acid-base balance in hepatocellular carcinoma, which may facilitate to invade portal vein.

摘要

背景

肝细胞癌是一种侵袭性恶性肿瘤,预后较差,即使肿瘤通过手术完全切除也容易复发。门静脉侵犯是导致肿瘤复发和预后不良的主要因素之一。然而,肝细胞癌为何容易长入血管尚不清楚。

方法

利用7例伴有门静脉血栓形成的肝细胞癌患者和7例无血管侵犯患者的手术标本,通过蛋白质组学技术分析蛋白质表达。肿瘤中的蛋白质通过二维电泳进行分离。凝胶中的蛋白质图谱记录为数字化图像。通过质谱鉴定伴有或不伴有门静脉血栓形成的肝细胞癌中表达的差异。

结果

临床上,伴有门静脉血栓形成的肿瘤比无门静脉血栓形成的肿瘤更大。伴有门静脉血栓形成的患者中位生存时间短得多[4(范围2.5 - 47)个月对53(范围33 - 85)个月,P = 0.002]。通过分析伴有或不伴有门静脉血栓形成的癌组织中的蛋白质表达,蛋白质表达差异主要为代谢酶。碳酸酐酶I、甜菜碱 - 高半胱氨酸 - 甲基转移酶1、延胡索酸水合酶、异戊酰辅酶A脱氢酶、短链特异性酰基辅酶A脱氢酶和精氨酸酶 - 1在伴有门静脉血栓形成的肿瘤中均下调。

结论

伴有门静脉血栓的肝细胞癌中代谢酶和胞质碳酸酐酶下调。代谢酶和胞质碳酸酐酶的缺乏可能改变肝细胞癌中的细胞代谢和酸碱平衡,这可能有助于侵袭门静脉。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58c0/5541415/fec19d40d7d6/12014_2017_9164_Fig1_HTML.jpg

相似文献

1
Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis.
Clin Proteomics. 2017 Aug 2;14:29. doi: 10.1186/s12014-017-9164-y. eCollection 2017.
2
Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
World J Gastroenterol. 2015 Jan 7;21(1):246-53. doi: 10.3748/wjg.v21.i1.246.
4
Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?
Liver Int. 2019 Feb;39(2):324-331. doi: 10.1111/liv.13988. Epub 2018 Nov 9.
6
Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma.
AJR Am J Roentgenol. 1993 Aug;161(2):229-33. doi: 10.2214/ajr.161.2.8392785.
7
Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis.
Jpn J Clin Oncol. 2012 Aug;42(8):721-9. doi: 10.1093/jjco/hys082. Epub 2012 Jun 11.

引用本文的文献

2
The Role of Mass Spectrometry in Hepatocellular Carcinoma Biomarker Discovery.
Metabolites. 2023 Oct 8;13(10):1059. doi: 10.3390/metabo13101059.
3
Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly.
World J Gastroenterol. 2023 Aug 7;29(29):4499-4527. doi: 10.3748/wjg.v29.i29.4499.
4
New Histamine-Related Five-Membered N-Heterocycle Derivatives as Carbonic Anhydrase I Activators.
Molecules. 2022 Jan 15;27(2):545. doi: 10.3390/molecules27020545.
5
Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer.
Cancers (Basel). 2021 Oct 19;13(20):5250. doi: 10.3390/cancers13205250.
6
TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma.
Cancers (Basel). 2019 Dec 25;12(1):68. doi: 10.3390/cancers12010068.

本文引用的文献

1
Fumarates and Cancer.
Trends Mol Med. 2017 Jan;23(1):3-5. doi: 10.1016/j.molmed.2016.12.001. Epub 2016 Dec 13.
4
Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era.
Eur J Surg Oncol. 2015 Sep;41(9):1144-52. doi: 10.1016/j.ejso.2015.05.024. Epub 2015 Jun 23.
5
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
Clin Mol Hepatol. 2015 Jun;21(2):115-21. doi: 10.3350/cmh.2015.21.2.115. Epub 2015 Jun 26.
6
A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability.
Ann Surg Oncol. 2013 Jan;20(1):325-39. doi: 10.1245/s10434-012-2513-1. Epub 2012 Nov 13.
7
Hepatocellular carcinoma.
Lancet. 2012 Mar 31;379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. Epub 2012 Feb 20.
8
Resection of hepatocellular carcinoma without cirrhosis.
Ann Surg. 2012 Jun;255(6):1135-43. doi: 10.1097/SLA.0b013e31823e70a3.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验